Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

  • Choose the service you want to log in to:

  • gov.je

    Update your notification preferences

  • one.gov.je

    Access government services

  • CAESAR

    Clear goods through customs or claim relief

  • Talentlink

    View or update your States of Jersey job application

Prescribed List: Changes from 1 September 2018

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 27 July 2018:

Decision Reference: MD-S-2018-0055

Decision Summary Title :

Prescribed List Changes 1 September 2018

Date of Decision Summary:

23 July 2018

Decision Summary Author:

Prescribing Advisor

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

Changes to be made to the Prescribed List as at 1 September 2018

Date of Written Report:

23 July 2018

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

Public

Subject:

Changes to be made to the Prescribed List (Jersey) as at 1 September 2018

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 September 2018 as set out in the accompanying report.

 

Reason(s) for Decision:

The Pharmaceutical Benefit Advisory Committee met on 19 June 2018 and has provided the Minister with a written report setting out its recommendations in respect of amendments to the Prescribed List.   The Minister accepted the following recommendations.

 

Items to be added to the Prescribed List

 

  1. Evolocumab 140mg/1ml solution for injection for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia in accordance with NICE TA394
  2. Escitalopram tablets 5mg, 10mg, 20mg (generic only) for the treatment of depression and anxiety disorders
  3. Tadalafil tablets 2.5mg, 5mg, 10mg, 20mg (generic only) for the treatment of erectile dysfunction 
  4. Trelegy Ellipta 92mcg/55mcg/22mcg dry powder inhaler (containing fluticasone + umeclidinium + vilanterol) for the treatment of chronic obstructive pulmonary disease
  5. Calcipotriol 50mcg/betamethasone 500mcg per gram cutaneous foam (Enstillar) for the treatment of psoriasis
  6. Vitamin E gel capsules 400IU for the treatment and prevention of vitamin deficiency

 

Items to be listed as generic only

 

  1. Nystatin with chlorhexidine (with and without hydrocortisone) cream and ointment

 

Other amendments to the Prescribed List

 

  1. Rosuvastatin 40mg strength tablet to be added in addition to all other strengths included in the List
  2. Gliclazide 40mg strength tablet to be added in addition to the one other strength included in the List
  3. Pregabalin oral solution 20mg/mL to be added in addition to the oral capsules included in the List
  4. Trimovate cream to be removed from the List as no licensed product is now available
  5. Triptorelin injection, which is already included in the List for the treatment of prostate cancer, to also be available for prescribing under shared care agreement for the management of gender dysphoria

 

In addition, the PBAC recommended discontinuation of the Jersey Dental List in favour of reimbursement for dental prescriptions in accordance with the Dental Practitioners’ Formulary for England and Wales.

 

The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their prescribers at a proportionate cost to the Fund.

Resource Implications:

The overall impact of the changes is expected to be an increase in total annual expenditure of around £50,000.  

Action required:

Pharmacy Advisor to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.

 

Signature:

Position:

Minister

Date Signed:

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button